This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Refino, C. J. Articles by Kirchhofer, D. Search for Related Content PubMed PubMed Citation Articles by Refino, C. J. Articles by Kirchhofer, D. Related Collections Exercise testing ACE/Angiotension receptors Pulmonary biology and circulation Other anticoagulants Other diagnostic testing

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:517.)
© 2002 American Heart Association, Inc.

Thrombosis

A Human Antibody That Inhibits Factor IX/IXa Function Potently Inhibits Arterial Thrombosis Without Increasing Bleeding

Canio J. Refino; Surinder Jeet; Leo DeGuzman; Stuart Bunting; Daniel Kirchhofer

From the Department of Physiology, Genentech Inc, South San Francisco, Calif.

Correspondence to Canio J. Refino, Genentech Inc, Physiology Dept, MS #42, 1 DNA Way, South San Francisco, CA 94080. E-mail ken{at}gene.com

10C12, a human antibody F(ab')₂, which specifically binds to the -carboxyglutamic acid domain of factor IX/factor IXa (F.IX/IXa), interferes with all known coagulation processes in which F.IX/IXa is involved. In a rabbit model of carotid artery injury, intravenous administration of 10C12 or heparin decreased thrombosis dose dependently. The dose that resulted in a 90% reduction of thrombus mass (ED₉₀) was a 30-µg/kg bolus of 10C12 or a 100-U/kg bolus plus 1.0 U · kg^-1 · min^-1 infusion of heparin. Heparin, at and below the ED₉₀, significantly prolonged coagulation times and cuticle bleeding times. In contrast, 10C12 had no effect on coagulation or bleeding times at doses up to 4 times the ED₉₀. To further evaluate the effect of 10C12 on bleeding, it was compared with heparin in a novel model of blood loss. At the ED₉₀ of heparin, blood loss induced by a standardized injury to the vasculature of the rabbit tibia increased to more than 2 times that of saline controls. In contrast, the dose of 10C12 required to produce a similar increase in blood loss was more than 30 times the ED₉₀. The antithrombotic potency and relative safety of this fully human antibody suggests that it may have therapeutic value for treatment of thrombotic disorders.

Key Words: thrombosis • factor IX • anticoagulants • antibody

This article has been cited by other articles:

				J. P. Sheehan and E. N. Walke Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism Blood, May 15, 2006; 107(10): 3876 - 3882. [Abstract] [Full Text] [PDF]

				J. Hirsh, M. O'Donnell, and J. I. Weitz New anticoagulants Blood, January 15, 2005; 105(2): 453 - 463. [Abstract] [Full Text] [PDF]

				P. P. Dobesh, K. Kim, and Z. Stacy The Future of Anticoagulation Journal of Pharmacy Practice, October 1, 2004; 17(5): 370 - 384. [Abstract] [PDF]

				M. Huang, B. C. Furie, and B. Furie Crystal Structure of the Calcium-stabilized Human Factor IX Gla Domain Bound to a Conformation-specific Anti-factor IX Antibody J. Biol. Chem., April 2, 2004; 279(14): 14338 - 14346. [Abstract] [Full Text] [PDF]

				P. C. Wong, E. J. Crain, C. A. Watson, A. M. Zaspel, M. R. Wright, P. Y. Lam, D. J. P. Pinto, R. R. Wexler, and R. M. Knabb Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 993 - 1000. [Abstract] [Full Text] [PDF]